Bristol Myers Squibb stock holds near recent highs as AI drug discovery pact and Houston build-out reshape its growth story

Bristol Myers Squibb stock (ISIN US0897961004) is trading close to the mid-$60 range, with recent quotes around $63.61 to $63.72 as of August 12, 2026, on the New York Stock Exchange, reflecting a steady year-to-date advance supported by portfolio growth and new strategic initiatives.

Latest price action and valuation backdrop

Recent market data from a US quote overview shows Bristol Myers Squibb closed at about $63.72 on August 12, 2026, a modest intraday gain of roughly 0.17% that keeps the shares near their recent high zone and signals continued investor interest at this level. The same data set lists another snapshot at approximately $63.61, underscoring that the stock has been consolidating tightly in the low-$60s over consecutive sessions rather than making abrupt moves.

According to a detailed sector review of the company’s performance, Bristol Myers Squibb shares have gained about 17.9% year to date in 2026, compared with roughly 6% growth for the broader large-cap pharmaceutical industry, indicating that the stock has been outperforming its peer group and that the current price embeds a premium for its execution on growth assets. The same analysis notes that the shares trade at roughly 9.63 times forward earnings, above the company’s own historical mean multiple of 8.62 times but still well below the large-cap pharma industry’s average valuation around 18.91 times forward earnings, suggesting that despite the rally the stock continues to trade at a relative discount to big-pharma peers.

Growth portfolio and earnings momentum

A recent fundamental breakdown highlights that Bristol Myers Squibb’s newer therapies are increasingly driving its top line. In the first half of 2026, sales from the company’s growth portfolio rose about 13%, lifting their contribution to roughly 56% of total revenues compared with 51.8% in the first half of 2025, a shift that shows how new medicines are gradually offsetting declines in legacy brands. This quantified change in mix - an increase of more than 4 percentage points in the growth segment’s share of total sales over one year - is central to the long-term investment case, as it indicates that higher-growth assets are now more than half of the business.

Consensus earnings expectations have also moved higher in recent weeks. Equity research data compiled in August 2026 shows the 2026 earnings per share consensus for Bristol Myers Squibb has risen to about $6.81 from $6.32 two months earlier, while the 2027 EPS consensus increased to about $6.42 from $6.05 over the same period. That upward revision of roughly $0.49 for 2026 and $0.37 for 2027 in just 60 days indicates that analysts have become more confident that the company’s pipeline and cost discipline can sustain mid-single-digit to high-single-digit earnings growth over the next two years.

AI-driven research pact and US manufacturing campus

Beyond the numbers, Bristol Myers Squibb is strengthening its research and production footprint in ways that matter for long-term growth. A recent collaboration with an AI-focused drug discovery specialist has drawn attention, with the partner’s shares surging after announcing an expanded pact that uses computational platforms to accelerate discovery of new compounds for oncology and other indications. The deal underlines Bristol Myers Squibb’s push to integrate advanced modeling and machine learning into its R&D engine, potentially shortening discovery cycles and improving hit rates for complex targets.

At the same time, a detailed feature on the company’s US manufacturing plans notes that Bristol Myers Squibb is investing about $2.3 billion in a new cell therapy and biologics campus in the Houston area. The planned site, described as a large-scale manufacturing hub, is expected to add capacity for commercial and clinical production of advanced therapies and could support future launches from the company’s pipeline. For investors, that scale of capital commitment - in the billions of dollars, fully dedicated to US infrastructure - reinforces the view that Bristol Myers Squibb is positioning itself for sustained volume growth in complex biologics and personalized medicines.

Representative product: cell therapy platform

One representative product area for Bristol Myers Squibb is its cell therapy portfolio, which includes CAR-T treatments for hematologic cancers that were acquired and developed through earlier strategic deals and internal research. These therapies aim to reprogram a patient’s own immune cells to recognize and destroy malignant cells, and their commercial rollout has helped drive the growth segment that now accounts for more than half of company revenues in the first half of 2026. As manufacturing capacity expands with the planned Houston campus, Bristol Myers Squibb should be better equipped to scale production volumes, support broader geographic launches and manage complex supply chains required for autologous cell therapies.

Shares consolidate near recent levels

Against this backdrop, Bristol Myers Squibb stock on the New York Stock Exchange continues to trade around the low-$60s, with recent quotes circling $63.61 to $63.72 as of August 12, 2026, on delayed intraday data, reflecting a consolidation phase after a roughly 17.9% year-to-date advance. For US investors, the current level near $64, combined with forward earnings expectations rising into the high-$6 per-share range and a valuation multiple still below the broader large-cap pharma average, frames the stock as a major biopharma name balancing legacy-drug headwinds with an increasingly meaningful growth portfolio and sizable US manufacturing and AI-enabled R&D investments.